The PALM clinical trial found that investigational drugs mAb114 and REGN-EB3 offered lower mortality rates compared to ZMapp, with mortality rates of 35% and 34%, respectively. Early diagnosis and treatment also improved survival chances.
Scientists developed an investigational vaccine that protected cynomolgus macaques against Ebola, Sudan, Marburg, and Lassa viruses, all causing severe disease and death. The quadrivalent VesiculoVax vaccine showed promising results in a study published in the Journal of Clinical Investigation.
A new risk assessment model accurately predicted Ebola's spread into Uganda by considering constant contacts and temporary interactions. The model helped allocate resources and prevent further spread in the country.
Researchers found filovirus antibodies in 5.9% of human samples and up to 13.3% of bat species, including those with Ebola virus, Bundibugyo virus, Sudan virus, Marburg virus, and Mengla virus antibodies. The study highlights the need for surveillance at the human-animal interface.
A study reveals that bats can transmit filoviruses to humans during bat-hunting festivals in Nagaland. The team found antibodies against two distinct filoviruses in human and bat blood samples, suggesting bats are the source of viral spillover events.
Researchers discovered that Ebola virus targets and disables T cells, a crucial line of defense, rendering infected individuals less able to combat the infection. This understanding could lead to new insights into immunosuppression and disease development in general.
Conflict events repeatedly reversed a declining phase of the Ebola epidemic in the Democratic Republic of Congo, according to researchers. Vaccination effectiveness was severely impacted by preceding unrest and subsequent conflict events, dropping from 52% to 4.8%.
A new study found that a highly diluted version of the Ebola vaccine remains fully protective against disease in monkeys. The findings suggest that the vaccine could be made more available by reducing its dosage, potentially easing production burdens.
A new UCL-developed model tracks ecosystem changes and human societies to predict Ebola outbreaks, identifying countries at risk in Africa. The model's results show that climate change and slower socioeconomic development increase the likelihood of outbreaks.
Scientists have decoded the immune response to the Ebola vaccine, revealing a broad range of antibodies against the virus. The research, led by Prof. Klein, found that different sites on the envelope protein of the virus were recognized and many antibodies exhibited high neutralising activity.
Researchers at the Weizmann Institute of Science and Germany's University of Cologne have identified two antibodies produced by vaccinated individuals that provide long-term immunity against Ebola. These antibodies, which target specific sites on the viral glycoprotein, demonstrate effective protection against the virus.
Researchers at Texas Biomed continue testing Ebola therapies and vaccines in human clinical trials, motivated by promising preclinical data. The goal is to positively impact human lives with effective treatments, building on previous studies involving nonhuman primates.
A study by Georgia State University researchers found that creating mutations in the VP35 protein of the Ebola virus can make it unable to cause disease. The mutated virus was able to induce strong immune responses in non-human primates, protecting them from infection with wildtype Ebola virus.
A new study demonstrates that a mutant live attenuated Ebola virus vaccine protects non-human primates against infection, targeting the immune-evasion function of VP35. The researchers developed a virus with three mutations in the VP35 protein, which plays a critical role in evading host immune responses.
A study found that mortality rates among Ebola survivors after hospital discharge were five times higher than expected in the general population. Those who stayed longer in treatment units had a higher mortality rate due to prolonged acute forms of the disease.
A community-based wildlife mortality surveillance system has been implemented in Republic of Congo to detect Ebola outbreaks early. The program, developed by WCS and NIH, reaches over 6,600 people and covers an area of 50,000 km2.
A new study suggests that nitazoxanide, an FDA-approved anti-parasitic drug, could potentially treat Ebola by enhancing the immune system's ability to detect the virus. The drug inhibited Ebola replication and worked by broadly amplifying the interferon pathway and cellular viral sensors.
Research finds that general fear orientation, trust in government, and perceived exposure likelihood significantly influence vaccination willingness. The study's findings suggest that social factors play a crucial role in shaping public health responses to infectious diseases.
Researchers estimate that at least half of Ebola outbreaks have gone undetected, resulting in hundreds of potential cases. The study highlights the need for improved detection and rapid response to prevent small outbreaks from growing into larger events.
A new study estimates that half of all Ebola outbreaks have gone undetected since the virus was discovered in 1976. The research highlights the need for improved detection and rapid response to prevent future epidemics.
Researchers developed a new methodology to calculate vulnerability based on adaptive capacity, which can help international bodies allocate resources. The study found that the most vulnerable states are not necessarily those with high confirmed cases, but rather those that struggle to cope with the disease.
Researchers found that Ebola survivors developed high levels of neutralizing antibodies months after recovery, which could inform the design of antiviral therapies and vaccines. The study's findings have implications for understanding immune protection after vaccination and developing effective treatments.
Researchers have generated two antibodies that potentially could be used in a simple filter paper test to detect Ebola virus. The study, published in the American Journal of Tropical Medicine & Hygiene, marks a breakthrough in diagnosing Ebola and Marburg viruses, which can cause severe bleeding and organ failure with high fatality rates.
A RIT professor developed a microfluidic device that detects the Ebola virus using CRISPR gene-editing technology, allowing for early treatment and potential outbreak control. The device can detect the virus within five minutes of combining automated sample processing and fluorescence sensing.
Researchers from The University of Queensland and Swansea University have found that environmental conditions play a key role in animal-to-human disease transfer. This new understanding could help predict the spread of emerging infectious diseases and prepare for future outbreaks.
Researchers found that Ebola survivors exhibit memory immune responses, including specific T cells against the virus, persisting over 2 years after infection. These findings could help develop more effective vaccines by boosting key immune cells needed for long-lasting protective immunity.
The New England Journal of Medicine advocates for standardized care in treating Ebola patients. Recent innovations, such as the Cube System, offer improved patient-centered care through continuous observation and accessibility.
Researchers at UTMB are developing rapid-acting vaccines and broad-spectrum treatments for Ebola and Marburg, two highly-lethal hemorrhagic fever viruses considered Tier 1 pathogens. The $35M NIH grant will support the creation of new vaccines and treatments to address high mortality rates ranging from 50-90%.
The Prometheus Center for Excellence in Translational Research aims to develop antibody-based therapies against four highly lethal viruses with no approved vaccines or treatments. The project will leverage existing research on ebolavirus and apply it to other emerging viruses, focusing on virus transmission from animals to humans.
The US FDA has approved the use of a rhesus macaque model to support the development of remdesivir, an investigational antiviral agent for treating Ebola virus infections. The study provides a framework for developing Ebola therapeutics under animal rule.
A survey of nearly 1,000 people in the Democratic Republic of Congo found that low public trust during the 2018 Ebola outbreak led to lower vaccination rates and increased refusal to seek care. Higher trust was linked to greater willingness to accept vaccination and seek medical attention.
Researchers have developed a simple model to understand the biomechanics of Ebola virus-host cell adhesion, which is essential for guiding the development of therapies. The model characterizes the interaction between the virus and cell surface receptors, providing new information on the road to developing an effective Ebola treatment.
Researchers found Ebola survivors in Liberia had higher rates of uveitis, muscle pain, fatigue, and joint pain compared to a control group. Physical exams also revealed abnormal findings in abdominal, chest, and neurologic areas.
A new pan-filovirus T-cell vaccine has been developed to protect against multiple filovirus species, including Ebola and Marburg. The vaccine induces killer T cells against conserved regions of inner filovirus proteins, offering potential protection against other known and unknown viruses in the filovirus family.
Researchers have discovered that bat influenza viruses can infect humans and livestock by using the MHC-II molecule to enter host cells. This finding suggests that these viruses have the potential to cause zoonotic transmission, leading to serious illnesses and deaths.
A new study found that genetic diversity is key to helping frogs survive the deadly Ranavirus disease. The research showed that a specific combination of immune genes can help tadpoles limit the severity of the virus. This finding has implications for frog species in Florida, which are threatened by the disease.
Researchers have found GS-441524 to be highly effective in treating FIP, with 26 out of 31 cats showing significant improvement in appetite and weight gain. The treatment has also been shown to be safe for cats of all ages and stages of the disease.
Researchers analyzed blood samples from Ebola patients in Sierra Leone to understand the progression of the disease and potential treatments. The study identified a critical role for choline and microvesicles in the virus's progression, with survivors showing higher levels of phosphatidylcholines and healthy individuals having lower PS...
Researchers at MUSC created an online software package to train health care workers using simulation in safe Ebola disease response, increasing knowledge of effective prevention by up to 19% and reducing critical errors. The program aims to reduce the number of critical errors and risky actions committed when treating an Ebola patient.
A Phase 1 clinical trial is underway at Cincinnati Children's Hospital Medical Center to test two experimental Ebola vaccines, ChAd3-EBO-Z and MVA-BN-Filo, for their safety and ability to produce an immune response. The trial aims to enroll up to 60 healthy volunteers between 18-45 years of age.
Researchers found genetic material and antibodies from the virus in a Greater Long-fingered bat in Liberia's Nimba District. The discovery adds to evidence suggesting bats serve as natural wildlife reservoirs for Ebola and other related viruses, shedding light on how outbreaks occur.
An investigational monoclonal antibody, mAb114, has been found to be safe and well-tolerated in an early-stage clinical trial involving adults. The treatment, which targets the Ebola virus's surface protein, demonstrated promising results, with all participants experiencing mild side effects.
A team of researchers at Texas Biomed has identified the interaction between an Ebola virus protein and a human cell protein that may be crucial to understanding the virus's life cycle. By studying this interaction in human cells using live virus, the scientists hope to develop potential drug targets to stop the disease.
A new high-throughput sequencing technique enables quick diagnosis of viruses like Ebola and Zika in the field, avoiding sample transfer. The technology has been validated in plant virology, paving the way for real-time detection of chronic or emerging plant viruses.
Scientists have developed a combination of monoclonal antibodies that protect animals from all three Ebola viruses, known to cause human disease. The experimental treatment, called MBP134, has shown broad protective efficacy in both animal models and large animal models.
Researchers have developed a two-antibody cocktail that protects nonhuman primates and ferrets against lethal Ebola virus infections of multiple strains. The breakthrough offers potential for a single-dose treatment to reduce healthcare worker burden during outbreaks.
Researchers have identified a new genus of filovirus from fruit bats in China, which shares similarities with Ebola and Marburg viruses. The Mengla virus has been found in different geographic locations than other filoviruses and poses a potential risk of interspecies transmission.
Researchers have identified a new genus of filovirus from a Rousettus bat in China, which shares genetic similarities with Ebola and Marburg viruses. The M?nglà virus poses a potential risk of interspecies transmission and has only been detected in bats so far.
A lab study identified key ways the three viruses hijack human cells and found at least one potential drug that can disrupt this process in human cells. Researchers also discovered how the Zika virus might cause microcephaly in infants, a crucial step towards developing a treatment.
Researchers discovered a human protein, RBBP6, that interferes with the Ebola virus replication cycle. By mimicking this protein's function, a small molecule drug could potentially block Ebola virus infection in human cells.
Researchers identified a new interaction between the Ebola virus protein VP30 and human host protein RBBP6, which disrupts virus growth. The study provides potential therapeutic targets for treating Ebola virus infections.
A new Ebola diagnostic test developed by David Sebba and colleagues offers a simple solution for detecting the disease in low-resource settings. The point-of-care test can distinguish between Ebola and other endemic diseases like Lassa fever and malaria within 30 minutes.
Researchers discovered that derivatives of amodiaquine can effectively block Ebola virus infection, with modified compounds showing improved potency and reduced toxicity. The findings offer a new therapeutic approach to treating patients infected with Ebola.
A randomized, controlled trial is enrolling patients with confirmed Ebola virus disease in the Democratic Republic of Congo to compare mortality among those receiving three investigational drugs with a control group. The trial aims to establish the safety and efficacy of these treatments in a comprehensive response to combat Ebola.
Scientists at The Wistar Institute have successfully engineered novel DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus, which offered complete and long-term protection against lethal virus challenges. The study provides a simple, rapid, and reproducible approach for immunization and evaluation of antibody efficacy.
Three experimental Ebola vaccines showed persistent immunity for at least two and a half years, driving new vaccine development against diseases like Lassa fever, Nipah virus disease, and MERS-CoV. The study's findings have implications far beyond the Ebola fight, providing insights that could expedite vaccine development.
Researchers aim to understand how malarial infections impact people exposed to Ebola virus, with a goal of developing tailored therapeutics for co-infection cases. The study will assess molecular impacts using an animal model and may involve testing in nonhuman primates.
Scientists have imaged the Ebola virus protein structure at near-atomic resolution, revealing a complex with individual RNA nucleotides and amino-acid side chains. This clarity may help find targets for antiviral drugs, one step closer to understanding how the whole virus works.
The WRAIR is conducting a Phase 1 clinical trial of the VRC-MARADC087-00-VP vaccine candidate, developed by NIAID, in healthy adult volunteers. The vaccine aims to stimulate rapid but durable immunity against Marburg virus, which causes severe hemorrhagic fever.
Researchers have developed a two-pronged approach targeting Ebola virus infection using linked nucleic acid (LNA) antisense oligonucleotides (ASOs). The study demonstrates effective targeting of two Ebola viral genes and the ability to prevent infectivity via Niemann-Pick C1.